Olokizumab Shows Efficacy After Nonresponse to TNF Inhibitors

The most likely use of olokizumab in clinical practice, if it is approved, is for patients with inadequate responses to TNF inhibitors.
MDedge News

source https://www.medscape.com/viewarticle/981624?src=rss